Latest Headlines
-
VantAI Collaborates With Google Cloud To Harness NVIDIA GPUs For Building Protein Interaction Foundation Models
5/1/2024
VantAI, a pioneer in generative AI-enabled drug discovery, is working with Google Cloud to power large scale distributed training and further improve internal operations.
-
Tsetse Fly Protein Provides Anti-Clotting Agent With Its Own On-Off Switch
5/1/2024
A completely novel way to develop 'surpamolecules' for drug discovery could have application in immunotherapy as well as this breakthrough design for an anticoagulant with on-demand reversibility.
-
Ingenium Therapeutics Novel NK Cell Therapy Receives Orphan Drug Designation From FDA
4/30/2024
Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, announced today that its investigational therapy IGNK001 (Gengluecel) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
-
Eton Pharmaceuticals Announces Submission To FDA Of New Drug Application For ET-400 (Hydrocortisone Oral Solution)
4/30/2024
Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of ET-400, Eton’s proprietary patented formulation of hydrocortisone oral solution.
-
Eluminex Biosciences Announces FDA Acceptance Of Investigational New Drug (IND) Application For EB-105 - A Novel Trispecific Fusion Antibody For Diabetic Macular Edema (DME) - And Upcoming Scientific Presentations
4/30/2024
Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics announced the acceptance of their EB-105 IND application to the US Food and Drug Administration (FDA) on April 26, 2024.
-
Neurocrine Biosciences Announces U.S. FDA Approval Of INGREZZA® SPRINKLE (valbenazine) Capsules
4/30/2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA® (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.1
-
Every Cure Deploys BioPhy’s Artificial Intelligence Platform To Accelerate Its Mission Of Repurposing Drugs For Untreated Diseases
4/30/2024
BioPhy, an innovative AI drug development company, today announced a partnership with Every Cure, a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.
-
New Drug Candidate Reverses Obesity In Mice
4/30/2024
Researchers at Karolinska Institutet may have found a new way to treat obesity and related disorders by targeting the cells’ powerhouses, the mitochondria.
-
MSD Joins The Open Targets Consortium
4/30/2024
Open Targets, a public-private partnership dedicated to pre-competitive drug discovery research, today announced MSD, the tradename of Merck & Co., Inc., Rahway, N.J., USA, as the latest partner to join the consortium.
-
Scenic Biotech Enters Into Research Collaboration With Bristol Myers Squibb
4/30/2024
Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.